AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

TELIX PHARMACEUTICALS LTD

15.610

-1.150-6.86%

Volume:1.76M

Turnover:27.98M

Market Cap:5.29B

PE:117.30

High:16.610

Open:16.450

Low:15.500

Close:16.760

52wk High:18.320

52wk Low:8.260

Shares:338.72M

Float Shares:275.41M

Volume Ratio:1.36

T/O Rate:0.64%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.133

EPS(LYR):-0.029

ROE:7.36%

ROA:2.71%

PB:7.77

PE(LYR):-530.29

Loading ...

Overview Company News Filings

Fast Growing Stocks With High Insider Ownership One Mines Titanium

Simply Wall St.

Gubra appoints Lena Moran-Adams group general counsel

Telix Pharmaceuticals (ASX:TLX) Shares Valuation After New Theranostics Collaboration With United Imaging

Simply Wall St.

Early ProstACT Phase 3 Safety Data Could Be A Game Changer For Telix (ASX:TLX)

Simply Wall St.

BUZZ-Morningstar says shares of Australia's Telix Pharmaceuticals undervalued

Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After United Imaging Deal And Phase 3 TLX591-Tx Update

Simply Wall St.

Stock Track | Telix Pharmaceuticals Soars 5.04% Intraday on Strong Growth Forecasts and Strategic Collaboration

What Telix Pharmaceuticals (ASX:TLX)'s ProstACT Safety Data and Theranostic Partnership Expansion Means For Shareholders

Simply Wall St.

Telix signs MOU with United Imaging to evaluate U.S. theranostics collaboration

Telix and United Imaging Announce Strategic Theranostics Collaboration

THOMSON REUTERS

BUZZ-Australia's Telix in focus as Citi signals confidence in prostate cancer drug

Telix Pharmaceuticals Says Prostate Cancer Treatement Candidate Shows Acceptable Tolerability in Phase Three Trial

MT Newswires Live

Telix publishes investor presentation outlining radiopharmaceutical growth strategy and pipeline updates

How Investors Are Reacting To Telix Pharmaceuticals (ASX:TLX) Glioblastoma Trial Enrolment Milestone

Simply Wall St.

A Look At Telix Pharmaceuticals’ Valuation As TLX101-Tx Glioblastoma Study Hits Key Safety Milestone

Simply Wall St.

ASX Biggest Losers

MT Newswires Live

Telix Pharmaceuticals Completes Enrollment in Brain Cancer Drug Trial

MT Newswires Live

Telix Pharmaceuticals files Form 3 as director Maria Rivas reports no holdings

Telix completes enrolment in IPAX-2 Phase 1 glioblastoma trial of TLX101-Tx

Ipax-2 Study of Tlx101-Tx in First-Line Glioblastoma Completes Enrolment and Confirms Dosing

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/TLX.AU/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":15.61,"timestamp":1789106064511,"preClose":16.76,"halted":0,"volume":1761148,"delay":0,"changeRate":-0.06861575178997625,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":275410996,"shares":338721355,"eps":0.13307551399939452,"marketStatus":"Trading","change":-1.15,"latestTime":"09-11 15:54:24 AEST","open":16.45,"high":16.61,"low":15.5,"amount":27980951,"amplitude":0.066229,"askPrice":15.61,"askSize":1001,"bidPrice":15.6,"bidSize":3915,"shortable":3,"etf":0,"ttmEps":0.13307551399939452,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789106400000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":16.76,"openAndCloseTimeList":[[1789084800000,1789106400000]],"volumeRatio":1.358066,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"TLX.AU","preClose":16.76,"auctionPrice":16.45,"auctionVolume":16131,"auctionTime":1789084747410,"referenceTime":1789036203090,"auction":1,"marketStatus":"盘前竞价","timestamp":1789084747410}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":275410996,"roa":"2.71%","roe":"7.36%","lyrEps":-0.029437,"volumeRatio":1.358066,"shares":338721355,"dividePrice":0,"high":16.61,"amplitude":0.066229,"preClose":16.76,"low":15.5,"week52Low":8.26,"pbRate":"7.77","psRate":"4.25","week52High":18.32,"institutionHeld":0,"latestPrice":15.61,"committee":0.592758,"eps":0.13307551399939452,"divideRate":0,"volume":1761148,"delay":0,"ttmEps":0.13307551399939452,"open":16.45,"prevYearClose":11.2,"prevWeekClose":16.47,"prevMonthClose":15.36,"prevQuarterClose":16.58,"fiveDayClose":16.47,"twentyDayClose":16.73,"sixtyDayClose":14.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787184000000,"name":null,"time":"","dateTimestamp":1787148000000,"actualEps":null},{"date":"2026-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771455600000,"name":null,"time":"","dateTimestamp":1771419600000,"actualEps":null},{"date":"2026-01-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1768777200000,"name":null,"time":"","dateTimestamp":1768741200000,"actualEps":null},{"date":"2025-08-21","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755734400000,"name":null,"time":"","dateTimestamp":1755698400000,"actualEps":null},{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2643763111","title":"Fast Growing Stocks With High Insider Ownership One Mines Titanium","url":"https://stock-news.laohu8.com/highlight/detail?id=2643763111","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643763111?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:27","pubTimestamp":1781612822,"startTime":"0","endTime":"0","summary":"With inflation paths tied to energy prices, central banks split between fresh hikes and extended pauses, and growth signals mixed from the US to China, many investors are looking for growth stories where management is financially invested alongside them. That is where the Fast Growing Stocks With High Insider Ownership screener can help. It focuses on companies with strong growth potential and optimistic outlooks from both analysts and executives. This article highlights 3 of the best stocks...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/2054000-choice2-main-header/1585187245570","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2054000-choice2-main-header/1585187245570"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-ipx/iperionx-shares/news/fast-growing-stocks-with-high-insider-ownership-one-mines-ti","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-ipx/iperionx-shares/news/fast-growing-stocks-with-high-insider-ownership-one-mines-ti","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX.AU","BK7067","AIPO","BK7095","TLX","BK4139","IPX.AU","LIN.AU","BK7116"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643736325","title":"Gubra appoints Lena Moran-Adams group general counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2643736325","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643736325?lang=en_us&edition=fundamental","pubTime":"2026-06-16 13:31","pubTimestamp":1781587873,"startTime":"0","endTime":"0","summary":"Gubra appointed Lena Moran-Adams as group general counsel, effective June 16, 2026.She will lead legal strategy and execution across the business, supporting pipeline development and strategic transactions.Moran-Adams previously served as group general counsel at Telix Pharmaceuticals.Her earlier roles included senior legal leadership posts at Gilead Sciences, Novartis, and Bristol Myers Squibb.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gubra A/S published the original content used to generate this news brief on June 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL6XlFb0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1670711123.USD","IE00B7SZLL34.SGD","LU0432979614.USD","LU1934455863.HKD","BK4007","BK4585","LU0965509283.SGD","LU0267386448.USD","BK4534","GILD","IE00BJJMRZ35.SGD","LU0058720904.USD","LU1868837136.USD","LU2242646821.SGD","LU2596442595.SGD","LU0985481810.HKD","LU0965509101.SGD","BK4566","BK4581","IE00B3T34201.USD","BK4550","LU1066051498.USD","LU0109394709.USD","LU1670710661.SGD","TLX.AU","BK4583","BK4559","BMY","IE00BFTCPJ56.SGD","BK7067","IE00BJT1NW94.SGD","LU0965508806.USD","LU0456855351.SGD","LU1037948897.HKD","LU0889565916.HKD","LU1430594728.SGD","IE0002141913.USD","LU1674673428.USD","IE00BSNM7G36.USD","LU0321505868.SGD","LU1868836914.USD","LU0882574055.USD","LU2125154935.USD","LU0965509010.AUD","LU1323610961.USD","LU1778281490.HKD","LU0823416689.USD","BK4568","LU2242652126.USD","IE00BFXG1179.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643878008","title":"Telix Pharmaceuticals (ASX:TLX) Shares Valuation After New Theranostics Collaboration With United Imaging","url":"https://stock-news.laohu8.com/highlight/detail?id=2643878008","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643878008?lang=en_us&edition=fundamental","pubTime":"2026-06-16 08:24","pubTimestamp":1781569466,"startTime":"0","endTime":"0","summary":"Why Telix’s new collaboration is back in focus for ASX:TLX holders\nTelix Pharmaceuticals (ASX:TLX) has drawn investor attention after signing a Memorandum of Understanding with United Imaging Healthcare North America to explore integrated theranostics workflows in the United States.\nThe collaboration centers on combining United Imaging Healthcare’s scanner platforms, software, connectivity and AI tools with Telix’s molecular imaging portfolio and clinical protocols, initially focusing on...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-shares-valuation-after-new-ther","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-shares-valuation-after-new-ther","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX","TLX.AU","BK7067","UBCP","BK4211","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643216838","title":"Early ProstACT Phase 3 Safety Data Could Be A Game Changer For Telix (ASX:TLX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2643216838","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643216838?lang=en_us&edition=fundamental","pubTime":"2026-06-13 07:26","pubTimestamp":1781306805,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals recently reported Part 1 data from its ProstACT Global Phase 3 trial in metastatic castration-resistant prostate cancer, showing TLX591-Tx had an acceptable safety and tolerability profile with no new safety signals when combined with standard-of-care therapies.\nThe findings underline a potentially differentiated safety profile versus existing PSMA-targeted radioligand therapies, with lower kidney and salivary gland exposure that may be clinically meaningful for...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/early-prostact-phase-3-safety-data-could-be-a-game-changer-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/early-prostact-phase-3-safety-data-could-be-a-game-changer-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX.AU","BK4139","BK7067","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642473434","title":"BUZZ-Morningstar says shares of Australia's Telix Pharmaceuticals undervalued","url":"https://stock-news.laohu8.com/highlight/detail?id=2642473434","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642473434?lang=en_us&edition=fundamental","pubTime":"2026-06-11 03:05","pubTimestamp":1781118347,"startTime":"0","endTime":"0","summary":"BUZZ-Morningstar says shares of Australia's Telix Pharmaceuticals undervalued** Morningstar maintains its fair value estimate of A$18 on Australia's Telix Pharmaceuticals TLX.AX, adding that the shares are undervalued and do not reflect co's growing market share in its core imaging products** Investment research firm says the product pipeline accounts for 10% of its fair value, with Pixclara and Zircaix targeting smaller markets than Illuccix, while ascribing a 25% approval probability for TLX591** Sees group revenue to grow at a five-year compound annual growth rate of 12%, driven by increased U.S. utilization of its core prostate imaging agents, and the rollout of new cancer imaging agents such as Pixclara and Zircaix** Sees TLX improving its gross margins, which is currently pressured by recent acquisition of RLS, by selling more higher-margin products over time** All 14 analysts rate the stock \"buy\" or higher with a median price target of A$21.90, as per data compiled by LSEG** Up ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nL6N42I184:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641178819","title":"Assessing Telix Pharmaceuticals (ASX:TLX) Valuation After United Imaging Deal And Phase 3 TLX591-Tx Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2641178819","media":"Simply Wall St.","labels":["corporation","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641178819?lang=en_us&edition=fundamental","pubTime":"2026-06-07 06:21","pubTimestamp":1780784516,"startTime":"0","endTime":"0","summary":"What the new United Imaging collaboration could mean for Telix\nTelix Pharmaceuticals (ASX:TLX) has signed a Memorandum of Understanding with United Imaging Healthcare North America to assess a U.S. focused research collaboration around integrated theranostics, immediately putting workflow and technology integration in the spotlight for investors.\nThe plan is to combine United Imaging’s scanner platforms, software, connectivity and AI tools with Telix’s molecular imaging portfolio and existing...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-unite","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/assessing-telix-pharmaceuticals-asxtlx-valuation-after-unite","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","UBCP","BK4139","TLX","TLX.AU","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195625663","title":"Stock Track | Telix Pharmaceuticals Soars 5.04% Intraday on Strong Growth Forecasts and Strategic Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=1195625663","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195625663?lang=en_us&edition=fundamental","pubTime":"2026-06-05 09:20","pubTimestamp":1780622433,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Limited (ASX:TLX) saw its shares surge 5.04% during intraday trading on Friday, as the biopharmaceutical company attracted investor attention following positive analysis of its...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640546711","title":"What Telix Pharmaceuticals (ASX:TLX)'s ProstACT Safety Data and Theranostic Partnership Expansion Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2640546711","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640546711?lang=en_us&edition=fundamental","pubTime":"2026-06-04 17:34","pubTimestamp":1780565694,"startTime":"0","endTime":"0","summary":"In recent days, Telix Pharmaceuticals reported Part 1 data from its Phase 3 ProstACT Global trial, showing TLX591-Tx had an acceptable safety and tolerability profile in combination with standard-of-care therapies for metastatic castration-resistant prostate cancer, and entered a Memorandum of Understanding in the U.S. with United Imaging Healthcare North America to explore integrated theranostics solutions beginning with TLX101-Px.\nTogether, these developments highlight Telix’s efforts to...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/what-telix-pharmaceuticals-asxtlxs-prostact-safety-data-and","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/what-telix-pharmaceuticals-asxtlxs-prostact-safety-data-and","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","TLX.AU","TLX","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640491277","title":"Telix signs MOU with United Imaging to evaluate U.S. theranostics collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2640491277","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640491277?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:02","pubTimestamp":1780398142,"startTime":"0","endTime":"0","summary":"Telix signed an MOU with United Imaging Healthcare North America to evaluate a U.S. research collaboration on integrated theranostics workflows.Work will pair United Imaging’s scanner platforms, software, connectivity, AI with Telix’s molecular imaging portfolio, protocols to standardize imaging performance.Initial U.S. focus on TLX101-Px , with potential expansion to other products, markets by mutual agreement.Early efforts target protocol optimization, workflow tool development, validation, pilot programs to support treatment planning, monitoring, longitudinal management.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL9rdvWn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00B3QW5Z07.USD","SG9999014021.USD","BK4588","LU2095319765.USD","SG9999014013.SGD","IE00BKPKM429.USD","BK4585","LU0314104364.USD","SG9999014039.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00BN0W2W23.USD","BK7067","LU2210150020.SGD","IE00BN0W2T93.GBP","TLX.AU","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014005.SGD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640491220","title":"Telix and United Imaging Announce Strategic Theranostics Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2640491220","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640491220?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:00","pubTimestamp":1780398002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nTUABXMLRV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640895991","title":"BUZZ-Australia's Telix in focus as Citi signals confidence in prostate cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2640895991","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640895991?lang=en_us&edition=fundamental","pubTime":"2026-06-02 11:22","pubTimestamp":1780370542,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Telix in focus as Citi signals confidence in prostate cancer drug  ** Shares of Telix Pharmaceuticals TLX.AX down 2.5% at A$12.69, tracking a 2% drop in the broader healthcare sub-index .AXHJ ** TLX stock in focus after Citi reiterated its \"buy\" stance, pointing to increased confidence in its lead prostate cancer drug candidate TLX591 following new data** Citi said trial data showed the drug was generally safe across combinations with standard prostate cancer treatments, with no signs it disrupted current care** Says at the latest data cut, most patients were still alive and many remained on treatment, suggesting stable outcome so far** Citi said the results support planned discussions with the U.S. FDA on moving the drug into the next stage of testing** All 14 analysts rate the stock \"buy\" or higher; their median PT is A$21.90 – LSEG-compiled data** Stock up 13.6% this year, including the day's move","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nL6N42A062:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640906993","title":"Telix Pharmaceuticals Says Prostate Cancer Treatement Candidate Shows Acceptable Tolerability in Phase Three Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640906993","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640906993?lang=en_us&edition=fundamental","pubTime":"2026-06-02 08:38","pubTimestamp":1780360721,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) said its lutetium radio antibody-drug conjugate candidate, TLX591-Tx, demonstrated acceptable tolerability across all standard-of-care combination groups in the ProstAC","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IND","TLX","TLX.AU","BK7067","BK7095","IND.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640161933","title":"Telix publishes investor presentation outlining radiopharmaceutical growth strategy and pipeline updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2640161933","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640161933?lang=en_us&edition=fundamental","pubTime":"2026-06-01 13:48","pubTimestamp":1780292897,"startTime":"0","endTime":"0","summary":"Telix outlined 16% quarter-on-quarter growth in Q1 2026 Precision Medicine sales to USD 186 million.Two FDA-cleared PSMA imaging agents now marketed across 22 countries; China NDA under NMPA review; Japan registration-enabling study underway.Glioma imaging agent Pixclara/Pixlumi flagged with a Sep. 11, 2026 PDUFA date; European MAA accepted.Renal mass imaging program advanced through two FDA Type A meetings; BLA resubmission in progress.Pipeline focus includes TLX591-Tx Phase 3 in PSMA+ mCRPC and TLX101-Tx pivotal recurrent GBM study; Precision Medicine growth framed at 20%-40% CAGR.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on June 01, 2026","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDLXMMVd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638656560","title":"How Investors Are Reacting To Telix Pharmaceuticals (ASX:TLX) Glioblastoma Trial Enrolment Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2638656560","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638656560?lang=en_us&edition=fundamental","pubTime":"2026-05-28 07:09","pubTimestamp":1779923368,"startTime":"0","endTime":"0","summary":"Earlier in May 2026, Telix Pharmaceuticals reported that its Phase 1 IPAX-2 trial of TLX101-Tx for newly diagnosed glioblastoma completed enrolment, with no dose-limiting toxicities observed so far at doses up to 10GBq alongside standard-of-care therapy.\nThis progress, together with ongoing Phase 3 evaluation of TLX101-Tx as the first radiopharmaceutical therapy to reach this stage in glioblastoma, highlights Telix’s attempt to build a differentiated neuro-oncology franchise using...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-investors-are-reacting-to-telix-pharmaceuticals-asxtlx-g","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-investors-are-reacting-to-telix-pharmaceuticals-asxtlx-g","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","BK7067","TLX.AU","TLX","ISBC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638515809","title":"A Look At Telix Pharmaceuticals’ Valuation As TLX101-Tx Glioblastoma Study Hits Key Safety Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2638515809","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638515809?lang=en_us&edition=fundamental","pubTime":"2026-05-26 17:30","pubTimestamp":1779787849,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has reached a key clinical milestone by completing enrolment in its Phase 1 IPAX-2 study of investigational radiopharmaceutical TLX101-Tx for newly diagnosed glioblastoma, with no dose-limiting toxicities reported at the highest doses tested.\nSee our latest analysis for Telix Pharmaceuticals.\nDespite the positive glioblastoma update and new prostate cancer imaging collaborations, Telix Pharmaceuticals' share price is down 11.21% over the past month but up 43.8%...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-valuation-as-tlx101-tx-gliob","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-valuation-as-tlx101-tx-gliob","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK7067","TLX","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638567399","title":"ASX Biggest Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2638567399","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638567399?lang=en_us&edition=fundamental","pubTime":"2026-05-26 11:36","pubTimestamp":1779766567,"startTime":"0","endTime":"0","summary":"Here are the ASX-listed companies with the biggest losses on Tuesday.ASX : -12%, AU$51.51Elevra : -7%, AU$12.75PEXA Group : -7%, AU$10.67Infratil : -5%, AU$12.29Yancoal Australia : -4%, AU$6.69Telix Pharmaceuticals : -4%, AU$12.82Challenger : -4%, AU$8.89Whitehaven Coal : -4%, AU$8.51Netwealth Group : -3%, AU$21.69Paladin Energy : -3%, AU$11.13","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7509","PDN.AU","BK7083","ELV.AU","WHC.AU","ASX.AU","BK7134","BK7062","BK7507","IFT.AU","BK7004","BK7095","CGF.AU","BK7006","TLX.AU","BK7112","YAL.AU","NWL.AU","BK7067","BK7039","BK7105","PXA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636500265","title":"Telix Pharmaceuticals Completes Enrollment in Brain Cancer Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2636500265","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636500265?lang=en_us&edition=fundamental","pubTime":"2026-05-19 06:52","pubTimestamp":1779144775,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  has completed patient enrolment in the IPAX-2 study evaluating TLX101-Tx in newly diagnosed glioblastoma, with the company reporting no dose-limiting toxicities observed to date, according to a Tuesday statement.The study is a dose-finding trial evaluating TLX101-Tx in combination with standard post-surgical radiotherapy and temozolomide, and it will proceed with follow-up to establish the maximum tolerated dose.Twelve patients were enrolled in three dose-escalation cohorts across four sites in Australia, Austria, and the Netherlands to assess safety, tolerability, and determine the maximum tolerated dose.TLX101-Tx is also being evaluated in the ongoing pivotal phase three IPAX BrIGHT trial for recurrent glioblastoma, which is currently enrolling patients across multiple countries.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TLX.AU","BK4139","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636040160","title":"Telix Pharmaceuticals files Form 3 as director Maria Rivas reports no holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2636040160","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636040160?lang=en_us&edition=fundamental","pubTime":"2026-05-19 06:32","pubTimestamp":1779143554,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals filed an initial Form 3 for director Maria Rivas dated May 11, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL9Nd1TQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636521001","title":"Telix completes enrolment in IPAX-2 Phase 1 glioblastoma trial of TLX101-Tx","url":"https://stock-news.laohu8.com/highlight/detail?id=2636521001","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636521001?lang=en_us&edition=fundamental","pubTime":"2026-05-19 05:01","pubTimestamp":1779138079,"startTime":"0","endTime":"0","summary":"Telix completed enrolment in its Phase 1 IPAX-2 study of TLX101-Tx in newly diagnosed glioblastoma.Interim safety observations have been positive, with dosing reaching the study maximum without dose-limiting toxicities; final confirmation of the maximum tolerated dose will come later when the trial completes, so results have not yet been formally presented.The update supports continued development of TLX101-Tx for first-line glioblastoma, a potential expansion beyond its ongoing Phase 3 IPAX BrIGHT program in recurrent disease.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL4BCY9y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4588","LU2210150020.SGD","NDAQ","TLX.AU","IE00BN0W2V16.EUR","LU0314104364.USD","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014021.USD","IE00B64PRP62.GBP","SG9999014005.SGD","IE00BGHQF748.EUR","LU2210149790.SGD","IE00BN0W2W23.USD","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","BK4112","BK7067","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636015570","title":"Ipax-2 Study of Tlx101-Tx in First-Line Glioblastoma Completes Enrolment and Confirms Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2636015570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636015570?lang=en_us&edition=fundamental","pubTime":"2026-05-19 05:00","pubTimestamp":1779138000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUA2ZMN1C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":198,"code":"91000000","status":"200"}]}}